Study to Evaluate Long-term Effectiveness and Safety, Patient Characteristics and Subjective Patient-reported Outcomes of Dupilumab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Under Real-world Conditions

This observational study tracks how well dupilumab (an injectable biologic drug) works in real-world clinical practice for people with COPD (chronic obstructive pulmonary disease) that remains uncontrolled despite standard inhaler treatments, and who have elevated blood eosinophils (a type of immune cell linked to inflammation). **You may be eligible if:** - You are an adult with COPD that remains poorly controlled despite being on combination inhaler therapy (LAMA/LABA/ICS or LAMA/LABA) - You have elevated blood eosinophil levels - Your doctor has decided to start you on dupilumab as part of your standard care - You are willing to allow your anonymized clinical data to be used in this study **You may NOT be eligible if:** - You do not meet the criteria for dupilumab according to the official prescribing information - You are currently in, or recently participated in, another study that might affect the results - You were hospitalized for a COPD flare-up within the past 4 weeks - You have a condition that limits your ability to complete questionnaires or participate Talk to your doctor to see if this trial is right for you.